Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Isomorphic Labs
Uses artificial intelligence and biological modeling to accelerate drug design.
What they do
Isomorphic Labs, an independent subsidiary of Alphabet, leverages the underlying architecture of AlphaFold to build predictive models of biological systems. The company partners with major pharmaceutical corporations to understand macromolecular structures and design entirely new small-molecule medicines.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Growth
- Headquarters
- London, UK
- Region
- Europe
- Founded
- 2021
- Total funding
- Undisclosed
Notable investors: Alphabet.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Demis Hassabis Raised $2.1B. The Money Is the Least Interesting Part.
Dr. Dereck Mush, MD, MBA